Bio-Gene Technology (ASX:BGT) Ending Cash Position: A$1.08 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Bio-Gene Technology Ending Cash Position?

Bio-Gene Technology ASX:BGT +4.55% Ending Cash Position is A$1.08 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Bio-Gene Technology's Ending Cash Position for the quarter that ended in Dec. 2025 was A$1.08 Mil.

Bio-Gene Technology's quarterly Ending Cash Position declined from Dec. 2024 (A$1.34 Mil) to Jun. 2025 (A$1.14 Mil) and declined from Jun. 2025 (A$1.14 Mil) to Dec. 2025 (A$1.08 Mil).

Bio-Gene Technology's annual Ending Cash Position declined from Jun. 2023 (A$2.99 Mil) to Jun. 2024 (A$2.21 Mil) and declined from Jun. 2024 (A$2.21 Mil) to Jun. 2025 (A$1.14 Mil).

Bio-Gene Technology Ending Cash Position Related Terms

Bio-Gene Technology Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology Ending Cash Position Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial 3.93 6.34 2.99 2.21 1.14

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.23 2.21 1.34 1.14 1.08

Bio-Gene Technology Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Bio-Gene Technology's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.209+-1.071
=1.14

Bio-Gene Technology's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.139+-0.058
=1.08

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$1.08 Mil mean?
Bio-Gene Technology (ASX:BGT) has a Ending Cash Position of A$1.08 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bio-Gene Technology and its competitors.
Is Bio-Gene Technology's Ending Cash Position too high?
Bio-Gene Technology's current Ending Cash Position is A$1.08 Mil.
How does Bio-Gene Technology's Ending Cash Position compare to VRTX and REGN?
Bio-Gene Technology's Ending Cash Position of A$1.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Bio-Gene Technology and its competitors. Bio-Gene Technology's current Ending Cash Position is A$1.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Ending Cash Position of A$1.08 Mil. The current Ending Cash Position is A$1.08 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Ending Cash Position is A$1.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.